Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Dendreon Jumps as More Doctors Prescribe Cancer Therapy

The Dendreon Corp. headquarters stands in Seattle, Washington. Photographer: Kevin  P. Casey/Bloomberg
The Dendreon Corp. headquarters stands in Seattle, Washington. Photographer: Kevin P. Casey/Bloomberg

Nov. 2 (Bloomberg) -- Dendreon Corp. rose the most in nine months after announcing a third-quarter loss that was less than analysts’ estimates and saying more doctors are using its prostate cancer drug Provenge.

The biotechnology company jumped 16 percent to $4.47 at the close in New York, its biggest single-day advance since Feb. 6. The Seattle-based drugmaker had a loss of 33 cents a share, excluding a restructuring charge. Analysts had expected a loss of 82 cents, according to the average of 22 estimates compiled by Bloomberg.

Urologists prescribing Provenge grew 14 percent in the quarter, Dendreon said today in a statement. The number of oncologists doing so fell by less than 1 percent, an improvement from an 8 percent slide in the second quarter. The medicine accounted for two-thirds of Dendreon’s sales last year and faces competition from new drugs from Johnson & Johnson and Medivation Inc.

“We delivered strong growth in urology and have continued to improve results in oncology,” Chief Executive Officer John H. Johnson said in a statement today.

The quarter’s net loss of $154.9 million, or $1.04 a share, compared with a net loss of $147.1 million, or $1, a year earlier, Dendreon said.

To contact the reporter on this story: Alex Nussbaum in New York at anussbaum1@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.